Lauren Rayner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lauren Rayner has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Hotopf
Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
20 shared publications - Irene J. Higginson
Cicely Saunders Institute of Palliative Care, Policy and Rehabilitation, King's College London, London, UK
10 shared publications Annabel Price
Department of Psychological Medicine, Institute of Psychiatry, King’s College London, London, UK
8 shared publications- Faith Matcham
School of Psychology, University of Sussex, Falmer, United Kingdom
6 shared publications Barbara Monroe
St Christopher’s Hospice, London, UK
5 shared publicationsNigel Sykes
St Christopher’s Hospice, London, UK
5 shared publications
Latest Publications
- Open Access
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 77 (6) , 598-606
Associations Between Depression, Arterial Stiffness, and Metabolic Syndrome Among Adults in the UK Biobank Population Study
People diagnosed with depression are at increased risk of major cardiovascular events (MACEs), including coronary heart disease and stroke.1-4 Arterial stiffness (AS), a hardening of the artery wall because of aging and diverse pathologic states, is a key mediator of MACE,5 and growing evidence has found an association of depression with AS.6 Components of metabolic syndrome (MetS), such as hypertension, dyslipidemia, obesity, and hyperglycemia, represent leading promoters of AS.5 Consistent with the key role of AS in predicting MACE incidence, carotid pulse wave velocity represents the criterion-standard measure for central AS,7,8 and several other noninvasive techniques (eg, photoplethysmography) are available as indicators of specific AS parameters (eg, wave reflections).5,9 While the interchangeability of these measures needs further research,10 they were found to be independently associated with incident MACE across different subgroups.9,11,12 Therefore, a key unanswered question for public health is the extent to which the adverse effect of depression on MACE might be mitigated by targeting modifiable metabolic mediators. To address this concern, we need to better understand the role of MetS in mediating the association of depression with AS. The extent to which this mediation differs by sex is critical given that the prevalence of MACE, MetS, and depression is often greater among women compared with men.13,14 Sex-specific mediating effects of MetS are generally underresearched but are a growing issue given the increasing prevalence of MetS in women.15 The present study adopted a mediation analysis approach to quantify to what extent MetS and its individual components mediated the association of depression with AS. The study also aimed to investigate the extent to which the hypothesized mediation varied by sex.
- 1 June 2020
- Published by American Medical Association (AMA) in JAMA Psychiatry
- Vol. 77 (6) , 598-606
Open AccessAssociations Between Depression, Arterial Stiffness, and Metabolic Syndrome Among Adults in the UK Biobank Population Study
People diagnosed with depression are at increased risk of major cardiovascular events (MACEs), including coronary heart disease and stroke.1-4 Arterial stiffness (AS), a hardening of the artery wall because of aging and diverse pathologic states, is a key mediator of MACE,5 and growing evidence has found an association of depression with AS.6 Components of metabolic syndrome (MetS), such as hypertension, dyslipidemia, obesity, and hyperglycemia, represent leading promoters of AS.5 Consistent with the key role of AS in predicting MACE incidence, carotid pulse wave velocity represents the criterion-standard measure for central AS,7,8 and several other noninvasive techniques (eg, photoplethysmography) are available as indicators of specific AS parameters (eg, wave reflections).5,9 While the interchangeability of these measures needs further research,10 they were found to be independently associated with incident MACE across different subgroups.9,11,12 Therefore, a key unanswered question for public health is the extent to which the adverse effect of depression on MACE might be mitigated by targeting modifiable metabolic mediators. To address this concern, we need to better understand the role of MetS in mediating the association of depression with AS. The extent to which this mediation differs by sex is critical given that the prevalence of MACE, MetS, and depression is often greater among women compared with men.13,14 Sex-specific mediating effects of MetS are generally underresearched but are a growing issue given the increasing prevalence of MetS in women.15 The present study adopted a mediation analysis approach to quantify to what extent MetS and its individual components mediated the association of depression with AS. The study also aimed to investigate the extent to which the hypothesized mediation varied by sex.
- 22 November 2019
- Published by BMJ
- Vol. 104 (Suppl 4) , A38
96 Value of an osteogenesis imperfecta clinical nurse specialist to families and external consultants in the UK
Objectives To ascertain if parents and consultants at secondary care level hospitals felt there were areas that the Clinical Nurse Specialists (CNS), working with children and families with Osteogenesis Imperfecta (OI) could improve upon within their service, and to gain feedback on the service provided. Methods A SurveyMonkey © questionnaire was created through the audit team at Great Ormond Street Hospital and the Paediatric Osteogenesis Imperfecta National Team (POINT) nursing break-out forum. These data were then compiled and collated into graphs and visual displays. Areas for improvement were fed back to individual services to consider how they may improve. Results 41 parents and 18 consultants completed questionnaires from 5 UK Hospitals, including the 4 designated Highly Specialised OI services in England. 85% of parents reported a CNS being present in their last OI appointment. 100% reported knowing how to contact the CNS. 82% agreed that The OI CNS role supports me managing my child’s OI. Areas to improve included: having more than 1 CNS, giving more information to schools and spending more time with the nurse at appointments. Additional comments included: Couldn’t be without our CNS; reassuring to have available; goes above and beyond. 89% of Consultants reported they were aware of a CNS in their regional OI centre. Contact reasons included: blood results, referral information, prenatal planning and medication queries. Benefits included: single point of contact, expert advice. 77% reported they agreed that The OI CNS is a good point of contact to assist me managing my OI patients. These data were exclusively linked to one centre reflecting a hub and spoke model of care, necessitated by the geographical location of patients. Conclusion Results showed that participants value the role of the CNS both as a point of contact and a source of specialist OI advice and support.
- 22 November 2019
- Published by BMJ
- Vol. 104 (Suppl 4) , A38
96 Value of an osteogenesis imperfecta clinical nurse specialist to families and external consultants in the UK
Objectives To ascertain if parents and consultants at secondary care level hospitals felt there were areas that the Clinical Nurse Specialists (CNS), working with children and families with Osteogenesis Imperfecta (OI) could improve upon within their service, and to gain feedback on the service provided. Methods A SurveyMonkey © questionnaire was created through the audit team at Great Ormond Street Hospital and the Paediatric Osteogenesis Imperfecta National Team (POINT) nursing break-out forum. These data were then compiled and collated into graphs and visual displays. Areas for improvement were fed back to individual services to consider how they may improve. Results 41 parents and 18 consultants completed questionnaires from 5 UK Hospitals, including the 4 designated Highly Specialised OI services in England. 85% of parents reported a CNS being present in their last OI appointment. 100% reported knowing how to contact the CNS. 82% agreed that The OI CNS role supports me managing my child’s OI. Areas to improve included: having more than 1 CNS, giving more information to schools and spending more time with the nurse at appointments. Additional comments included: Couldn’t be without our CNS; reassuring to have available; goes above and beyond. 89% of Consultants reported they were aware of a CNS in their regional OI centre. Contact reasons included: blood results, referral information, prenatal planning and medication queries. Benefits included: single point of contact, expert advice. 77% reported they agreed that The OI CNS is a good point of contact to assist me managing my OI patients. These data were exclusively linked to one centre reflecting a hub and spoke model of care, necessitated by the geographical location of patients. Conclusion Results showed that participants value the role of the CNS both as a point of contact and a source of specialist OI advice and support.
- Open Access
- 1 May 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (5) , 688-695
Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation
Objective There is inconsistent evidence about the association between inflammatory disorders and depression and anxiety onset in a primary care context. The study aimed to evaluate the risk of depression and anxiety within multisystem and organ-specific inflammatory disorders. Methods This is a prospective cohort study with primary care patients from the UK Clinical Practice Research Datalink diagnosed with an inflammatory disorder between 1 January 2001 and 31 December 2016. These patients were matched on age, gender, practice and index date with patients without an inflammatory disorder. The study exposures were seven chronic inflammatory disorders. Clinical diagnosis of depression and anxiety represented the outcome measures of interest. Results Among 538 707 participants, the incidence of depression ranged from 14 per 1000 person-years (severe psoriasis) to 9 per 1000 person-years (systemic vasculitis), substantively higher compared with their comparison group (5–7 per 1000 person-years). HRs of multiple depression and anxiety events were 16% higher within inflammatory disorders (HR, 1.16, 95% CI 1.12 to 1.21, pConclusions Primary care patients with inflammatory disorders have elevated rates of depression and anxiety incidence, particularly those patients with early-onset inflammatory disorders. This finding may reflect the impact of the underlying disease on patients’ quality of life, although the precise mechanisms require further investigation.
- 1 May 2019
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 78 (5) , 688-695
Open AccessCommon mental disorders within chronic inflammatory disorders: a primary care database prospective investigation
Objective There is inconsistent evidence about the association between inflammatory disorders and depression and anxiety onset in a primary care context. The study aimed to evaluate the risk of depression and anxiety within multisystem and organ-specific inflammatory disorders. Methods This is a prospective cohort study with primary care patients from the UK Clinical Practice Research Datalink diagnosed with an inflammatory disorder between 1 January 2001 and 31 December 2016. These patients were matched on age, gender, practice and index date with patients without an inflammatory disorder. The study exposures were seven chronic inflammatory disorders. Clinical diagnosis of depression and anxiety represented the outcome measures of interest. Results Among 538 707 participants, the incidence of depression ranged from 14 per 1000 person-years (severe psoriasis) to 9 per 1000 person-years (systemic vasculitis), substantively higher compared with their comparison group (5–7 per 1000 person-years). HRs of multiple depression and anxiety events were 16% higher within inflammatory disorders (HR, 1.16, 95% CI 1.12 to 1.21, pConclusions Primary care patients with inflammatory disorders have elevated rates of depression and anxiety incidence, particularly those patients with early-onset inflammatory disorders. This finding may reflect the impact of the underlying disease on patients’ quality of life, although the precise mechanisms require further investigation.
- 1 March 2019
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 34 (2) , 65-75
Efficacy and acceptability of antidepressants in patients with ischemic heart disease
To assess the efficacy and acceptability of antidepressants in adults with ischemic heart disease (IHD). We gathered all available randomized-controlled trials comparing antidepressants versus placebo or other antidepressants in adults with IHD. The primary outcome was depressive symptoms at the study endpoint, as measured by validated rating scales. We pooled data in a meta-analysis using a random-effects model. The confidence in the estimates (or certainty of the evidence) was assessed using the GRADE approach. Antidepressants appeared to be more effective than placebo in reducing depressive symptoms (11 comparisons; 1685 participants; standardized mean difference −0.71, 95% confidence interval: −1.11 to −0.30; GRADE quality: moderate). This result was confirmed in the subgroup of serotonin selective reuptake inhibitors, and for the single drugs sertraline and citalopram, with a greater magnitude of effect and a higher quality of evidence for the former. No differences between antidepressants and placebo emerged in terms of acceptability and tolerability, quality of life, mortality, and cardiovascular events. Only two small head-to-head studies were identified. Sertraline is a reasonable first-line choice in patients with IHD and depression, whereas the role of citalopram as the first-line agent should be reconsidered.
- 1 March 2019
- Published by Wolters Kluwer Health in International Clinical Psychopharmacology
- Vol. 34 (2) , 65-75
Efficacy and acceptability of antidepressants in patients with ischemic heart disease
To assess the efficacy and acceptability of antidepressants in adults with ischemic heart disease (IHD). We gathered all available randomized-controlled trials comparing antidepressants versus placebo or other antidepressants in adults with IHD. The primary outcome was depressive symptoms at the study endpoint, as measured by validated rating scales. We pooled data in a meta-analysis using a random-effects model. The confidence in the estimates (or certainty of the evidence) was assessed using the GRADE approach. Antidepressants appeared to be more effective than placebo in reducing depressive symptoms (11 comparisons; 1685 participants; standardized mean difference −0.71, 95% confidence interval: −1.11 to −0.30; GRADE quality: moderate). This result was confirmed in the subgroup of serotonin selective reuptake inhibitors, and for the single drugs sertraline and citalopram, with a greater magnitude of effect and a higher quality of evidence for the former. No differences between antidepressants and placebo emerged in terms of acceptability and tolerability, quality of life, mortality, and cardiovascular events. Only two small head-to-head studies were identified. Sertraline is a reasonable first-line choice in patients with IHD and depression, whereas the role of citalopram as the first-line agent should be reconsidered.
- Open Access
- 1 October 2016
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 89, 53-60
Mental disorder in limb reconstruction: Prevalence, associations and impact on work disability
- 1 October 2016
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 89, 53-60
Open AccessMental disorder in limb reconstruction: Prevalence, associations and impact on work disability
- Top Cited PapersOpen Access
- 8 March 2016
- Published by Wolters Kluwer Health in Pain
- Vol. 157 (7) , 1472-1479
Depression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs
This cross-sectional study aimed to determine the prevalence and impact of depression on health care costs in patients with complex chronic pain. The sample included 1204 patients attending a tertiary pain management service for people with chronic disabling pain, unresponsive to medical treatment. As part of routine care, patients completed a web-based questionnaire assessing mental and physical health, functioning, and service use in the preceding 3 months. Depression was assessed using the 9-item Patient Health Questionnaire. Self-report health care utilisation was measured across 4 domains: general practitioner contacts, contacts with secondary/tertiary care doctors, accident and emergency department visits, and days hospitalised. The participation rate was 89%. Seven hundred and thirty-two patients (60.8%; 95% CI 58.0-63.6) met criteria for probable depression, and 407 (33.8%) met the threshold for severe depression. Patients with depression were more likely to be unable to work because of ill health and reported greater work absence, greater pain-related interference with functioning, lower pain acceptance, and more generalised pain. Mean total health care costs per 3-month period were £731 (95% CI £646-£817) for patients with depression, compared with £448 (95% CI £366-£530) for patients without depression. A positive association between severe depression and total health care costs persisted after controlling for key demographic, functional, and clinical covariates using multiple linear regression models. These findings reveal the extent, severity, and impact of depression in patients with chronic pain and make evident a need for action. Effective treatment of depression may improve patient health and functioning and reduce the burden of chronic pain on health care services.
- 8 March 2016
- Published by Wolters Kluwer Health in Pain
- Vol. 157 (7) , 1472-1479
Top Cited PapersOpen AccessDepression in patients with chronic pain attending a specialised pain treatment centre: prevalence and impact on health care costs
This cross-sectional study aimed to determine the prevalence and impact of depression on health care costs in patients with complex chronic pain. The sample included 1204 patients attending a tertiary pain management service for people with chronic disabling pain, unresponsive to medical treatment. As part of routine care, patients completed a web-based questionnaire assessing mental and physical health, functioning, and service use in the preceding 3 months. Depression was assessed using the 9-item Patient Health Questionnaire. Self-report health care utilisation was measured across 4 domains: general practitioner contacts, contacts with secondary/tertiary care doctors, accident and emergency department visits, and days hospitalised. The participation rate was 89%. Seven hundred and thirty-two patients (60.8%; 95% CI 58.0-63.6) met criteria for probable depression, and 407 (33.8%) met the threshold for severe depression. Patients with depression were more likely to be unable to work because of ill health and reported greater work absence, greater pain-related interference with functioning, lower pain acceptance, and more generalised pain. Mean total health care costs per 3-month period were £731 (95% CI £646-£817) for patients with depression, compared with £448 (95% CI £366-£530) for patients without depression. A positive association between severe depression and total health care costs persisted after controlling for key demographic, functional, and clinical covariates using multiple linear regression models. These findings reveal the extent, severity, and impact of depression in patients with chronic pain and make evident a need for action. Effective treatment of depression may improve patient health and functioning and reduce the burden of chronic pain on health care services.
- Open Access
- 1 May 2014
- Published by Elsevier in General Hospital Psychiatry
- Vol. 36 (3) , 318-324
Embedding integrated mental health assessment and management in general hospital settings: feasibility, acceptability and the prevalence of common mental disorder
- 1 May 2014
- Published by Elsevier in General Hospital Psychiatry
- Vol. 36 (3) , 318-324
Open AccessEmbedding integrated mental health assessment and management in general hospital settings: feasibility, acceptability and the prevalence of common mental disorder
- Open Access
- 1 March 2014
- Published by Elsevier in Clinical Psychology Review
- Vol. 34 (2) , 141-157
Self-help interventions for symptoms of depression, anxiety and psychological distress in patients with physical illnesses: A systematic review and meta-analysis
- 1 March 2014
- Published by Elsevier in Clinical Psychology Review
- Vol. 34 (2) , 141-157
Open AccessSelf-help interventions for symptoms of depression, anxiety and psychological distress in patients with physical illnesses: A systematic review and meta-analysis
- Top Cited PapersOpen Access
- 3 September 2013
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (12) , 2136-2148
The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis
Objective. There is substantial uncertainty regarding the prevalence of depression in RA. We conducted a systematic review aiming to describe the prevalence of depression in RA. Methods. Web of Science, PsycINFO, CINAHL, Embase, Medline and PubMed were searched for cross-sectional studies reporting a prevalence estimate for depression in adult RA patients. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and a meta-analysis was performed. Results. A total of 72 studies, including 13 189 patients, were eligible for inclusion in the review. Forty-three methods of defining depression were reported. Meta-analyses revealed the prevalence of major depressive disorder to be 16.8% (95% CI 10%, 24%). According to the PHQ-9, the prevalence of depression was 38.8% (95% CI 34%, 43%), and prevalence levels according to the HADS with thresholds of 8 and 11 were 34.2% (95% CI 25%, 44%) and 14.8% (95% CI 12%, 18%), respectively. The main influence on depression prevalence was the mean age of the sample. Conclusion. Depression is highly prevalent in RA and associated with poorer RA outcomes. This suggests that optimal care of RA patients may include the detection and management of depression.
- 3 September 2013
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 52 (12) , 2136-2148
Top Cited PapersOpen AccessThe prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis
Objective. There is substantial uncertainty regarding the prevalence of depression in RA. We conducted a systematic review aiming to describe the prevalence of depression in RA. Methods. Web of Science, PsycINFO, CINAHL, Embase, Medline and PubMed were searched for cross-sectional studies reporting a prevalence estimate for depression in adult RA patients. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and a meta-analysis was performed. Results. A total of 72 studies, including 13 189 patients, were eligible for inclusion in the review. Forty-three methods of defining depression were reported. Meta-analyses revealed the prevalence of major depressive disorder to be 16.8% (95% CI 10%, 24%). According to the PHQ-9, the prevalence of depression was 38.8% (95% CI 34%, 43%), and prevalence levels according to the HADS with thresholds of 8 and 11 were 34.2% (95% CI 25%, 44%) and 14.8% (95% CI 12%, 18%), respectively. The main influence on depression prevalence was the mean age of the sample. Conclusion. Depression is highly prevalent in RA and associated with poorer RA outcomes. This suggests that optimal care of RA patients may include the detection and management of depression.
- 9 August 2013
- Published by SAGE Publications in Palliative Medicine
- Vol. 28 (3) , 243-255
I’ve had a good life, what’s left is a bonus: Factor analysis of the Mental Adjustment to Cancer Scale in a palliative care population
Background: The Mental Adjustment to Cancer Scale is an assessment tool commonly used to measure coping in cancer patients, which characterises adaptive coping under the label of ‘fighting spirit’. Aim: This study explores adaptation in patients with advanced cancer, by examining the factor structure of the Mental Adjustment to Cancer Scale. Further aims were to examine associations between types of coping and psychological outcomes measured at the same time (time 1) and 4 weeks after referral to palliative care services (time 2). Design: A cross-sectional study with a follow-up assessment 4 weeks later. Factor analysis examined the structure of the Mental Adjustment to Cancer Scale at time 1. Setting/participants: A total of 275 patients with advanced cancer receiving palliative care, of whom 193 took part at follow-up. Results: This study provided evidence for the internal consistency and validity of a new scale of ‘acceptance and positivity’ for use in advanced cancer patients. Patients with a desire for hastened death had lower acceptance and positivity, and patients with higher global quality of life reported a higher level. Social support was positively associated with acceptance and positivity. Higher scores on the acceptance and positivity scale were associated with reduced odds of a desire for hastened death at time 2. Conclusion: Adaptation to advanced cancer differs from adaptation to early stage cancer, comprising a general acceptance of the illness and trying to make the most of the time that is left. Individuals with low social support were less likely to evidence appropriate adaptation to their illness.
- 9 August 2013
- Published by SAGE Publications in Palliative Medicine
- Vol. 28 (3) , 243-255
I’ve had a good life, what’s left is a bonus: Factor analysis of the Mental Adjustment to Cancer Scale in a palliative care population
Background: The Mental Adjustment to Cancer Scale is an assessment tool commonly used to measure coping in cancer patients, which characterises adaptive coping under the label of ‘fighting spirit’. Aim: This study explores adaptation in patients with advanced cancer, by examining the factor structure of the Mental Adjustment to Cancer Scale. Further aims were to examine associations between types of coping and psychological outcomes measured at the same time (time 1) and 4 weeks after referral to palliative care services (time 2). Design: A cross-sectional study with a follow-up assessment 4 weeks later. Factor analysis examined the structure of the Mental Adjustment to Cancer Scale at time 1. Setting/participants: A total of 275 patients with advanced cancer receiving palliative care, of whom 193 took part at follow-up. Results: This study provided evidence for the internal consistency and validity of a new scale of ‘acceptance and positivity’ for use in advanced cancer patients. Patients with a desire for hastened death had lower acceptance and positivity, and patients with higher global quality of life reported a higher level. Social support was positively associated with acceptance and positivity. Higher scores on the acceptance and positivity scale were associated with reduced odds of a desire for hastened death at time 2. Conclusion: Adaptation to advanced cancer differs from adaptation to early stage cancer, comprising a general acceptance of the illness and trying to make the most of the time that is left. Individuals with low social support were less likely to evidence appropriate adaptation to their illness.